Ito H, Takagi Y, Ando Y, Kubo A, Hashimoto S, Tsutsui F, Kurihara S
Obstet Gynecol. 1980 Mar;55(3):358-62. doi: 10.1097/00006250-198003000-00018.
Serum ferritin levels were determined by a radioimmunoassay (a 2-site solid-phase method). The mean ferritin level for 52 control women was 35 ng/ml, and the 2nd to 98th percentile reference intervals were 3.9 to 108 ng/ml. The upper limit of ferritin level for controls was determined to be 108 ng/ml, and the sera from cervical cancer patients were screened. In 98 patients with untreated cervical cancer, 50 (51%) had elevated levels of serum ferritin. Among 36 patients who were surgically treated and whose resected specimens were pathologically examined, 12 of 16 patients (75%) with ferritin levels above normal and 3 of 20 patients (15%) with levels below 108 ng/ml had parametrial invasion and/or lymph node metastasis. Serum ferritin levels were measured at 2- to 4-week intervals and 6 months after treatment on 21 patients with levels elevated before therapy. Ferritin levels decreased to the normal range 4 weeks after treatment in many patients, but the development of elevated levels thereafter was closely associated with a poor prognosis. Measurement of serum ferritin may be useful in predicting the extent of cancer beyond the cervix and the prognosis for cervical cancer patients.
血清铁蛋白水平通过放射免疫测定法(一种双位点固相法)测定。52名对照女性的平均铁蛋白水平为35 ng/ml,第2至98百分位数的参考区间为3.9至108 ng/ml。对照的铁蛋白水平上限确定为108 ng/ml,并对宫颈癌患者的血清进行筛查。在98例未经治疗的宫颈癌患者中,50例(51%)血清铁蛋白水平升高。在36例接受手术治疗且切除标本经病理检查的患者中,铁蛋白水平高于正常的16例患者中有12例(75%)以及铁蛋白水平低于108 ng/ml的20例患者中有3例(15%)存在宫旁浸润和/或淋巴结转移。对21例治疗前铁蛋白水平升高的患者,在治疗后每隔2至4周以及6个月测量血清铁蛋白水平。许多患者在治疗后4周铁蛋白水平降至正常范围,但此后水平升高与预后不良密切相关。测定血清铁蛋白可能有助于预测宫颈癌超出宫颈的范围以及宫颈癌患者的预后。